# Exicure, Inc.: financial statements, quarterly

XCUR · Nasdaq · CIK 1698530 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xcur.md) · [Financials](/companies/xcur/financials.md) · [Filings](/companies/xcur/filings.md) · [Insiders](/companies/xcur/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xcur/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0001698530-24-000117.md) | [0.0 d](/filings/0001698530-25-000019.md) | [500](/filings/0001698530-25-000056.md) | [0.0](/filings/0001698530-25-000077.md) | [0.0](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | [0.0](/filings/0001698530-26-000057.md) | [0.0](/filings/0001193125-26-352011.md) | [0.0](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | [0.0](/filings/0001698530-26-000057.md) | [0.0](/filings/0001193125-26-352011.md) |
| Research and development | $k | [0.0](/filings/0001698530-24-000117.md) | [0.0 d](/filings/0001698530-25-000019.md) | [0.0](/filings/0001698530-25-000056.md) | [0.0](/filings/0001698530-25-000077.md) | [0.0](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | [808](/filings/0001698530-26-000057.md) | [935](/filings/0001193125-26-352011.md) | [888](/filings/0001698530-25-000100.md) | [655 d](/filings/0001698530-26-000028.md) | [312](/filings/0001698530-26-000057.md) | [174](/filings/0001193125-26-352011.md) |
| Operating income | $k | [(3,317)](/filings/0001698530-24-000117.md) | [(1,498) d](/filings/0001698530-25-000019.md) | [(836)](/filings/0001698530-25-000056.md) | [(1,235)](/filings/0001698530-25-000077.md) | [(2,572)](/filings/0001698530-25-000100.md) | [(7,589) d](/filings/0001698530-26-000028.md) | [2,923](/filings/0001698530-26-000057.md) | [(2,509)](/filings/0001193125-26-352011.md) | [(2,391)](/filings/0001698530-25-000100.md) | [(2,256) d](/filings/0001698530-26-000028.md) | [(1,640)](/filings/0001698530-26-000057.md) | [(1,054)](/filings/0001193125-26-352011.md) |
| Interest expense | $k | [0.0](/filings/0001698530-24-000030.md) | [0.0 d](/filings/0001698530-24-000051.md) | not reported | [6.0](/filings/0001698530-24-000089.md) | [12.0](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | not reported | not reported | [0.0](/filings/0001698530-25-000100.md) | [1.0 d](/filings/0001698530-26-000028.md) | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001698530-24-000117.md) | [0.0 d](/filings/0001698530-25-000019.md) | [0.0](/filings/0001698530-25-000056.md) | [0.0](/filings/0001698530-25-000077.md) | [8.0](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | [0.0](/filings/0001698530-26-000057.md) | [0.0](/filings/0001193125-26-352011.md) | [0.0](/filings/0001698530-25-000100.md) | [(634) d](/filings/0001698530-26-000028.md) | [0.0](/filings/0001698530-26-000057.md) | [0.0](/filings/0001193125-26-352011.md) |
| Net income | $k | [(5,256)](/filings/0001698530-24-000117.md) | [(1,487) d](/filings/0001698530-25-000019.md) | [(829)](/filings/0001698530-25-000100.md) | [(600)](/filings/0001698530-25-000100.md) | [(1,091)](/filings/0001698530-25-000100.md) | [(7,181) d](/filings/0001698530-26-000028.md) | [3,010](/filings/0001193125-26-352011.md) | [(2,621)](/filings/0001193125-26-352011.md) | [(2,437)](/filings/0001698530-25-000100.md) | [(2,898) d](/filings/0001698530-26-000028.md) | [(1,828)](/filings/0001193125-26-352011.md) | [(1,121)](/filings/0001193125-26-352011.md) |
| Diluted EPS | $ per share | [(3.04)](/filings/0001698530-24-000117.md) | not reported | [(0.48)](/filings/0001698530-25-000056.md) | [(0.35)](/filings/0001698530-25-000077.md) | [(0.57)](/filings/0001698530-25-000100.md) | not reported | [0.49](/filings/0001698530-26-000057.md) | [(0.41)](/filings/0001193125-26-352011.md) | [(0.39)](/filings/0001698530-25-000100.md) | not reported | [(0.29)](/filings/0001698530-26-000057.md) | [(0.18)](/filings/0001193125-26-352011.md) |
| Basic EPS | $ per share | [(3.04)](/filings/0001698530-24-000117.md) | not reported | [(0.48)](/filings/0001698530-25-000056.md) | [(0.35)](/filings/0001698530-25-000077.md) | [(0.57)](/filings/0001698530-25-000100.md) | not reported | [0.49](/filings/0001698530-26-000057.md) | [(0.41)](/filings/0001193125-26-352011.md) | [(0.39)](/filings/0001698530-25-000100.md) | not reported | [(0.29)](/filings/0001698530-26-000057.md) | [(0.18)](/filings/0001193125-26-352011.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.9](/filings/0001698530-24-000030.md) | [0.8](/filings/0001698530-24-000117.md) | [0.4](/filings/0001698530-24-000068.md) | [0.5](/filings/0001698530-24-000089.md) | [0.3](/filings/0001698530-24-000117.md) | [12.5](/filings/0001698530-25-000100.md) | [10.4](/filings/0001698530-25-000056.md) | [7.9](/filings/0001698530-25-000077.md) | [4.4](/filings/0001698530-25-000100.md) | not reported | not reported | not reported |
| Current assets | $m | [3.1](/filings/0001698530-24-000030.md) | [2.0](/filings/0001698530-25-000019.md) | [1.5](/filings/0001698530-24-000068.md) | [2.1](/filings/0001698530-24-000089.md) | [2.6](/filings/0001698530-24-000117.md) | [13.7](/filings/0001698530-26-000028.md) | [11.3](/filings/0001698530-25-000056.md) | [8.6](/filings/0001698530-25-000077.md) | [5.4](/filings/0001698530-25-000100.md) | [4.6](/filings/0001193125-26-352011.md) | [3.5](/filings/0001698530-26-000057.md) | [2.3](/filings/0001193125-26-352011.md) |
| Total assets | $m | [13.0](/filings/0001698530-24-000030.md) | [11.6](/filings/0001698530-25-000019.md) | [10.7](/filings/0001698530-24-000068.md) | [10.7](/filings/0001698530-24-000089.md) | [10.6](/filings/0001698530-24-000117.md) | [15.1](/filings/0001698530-26-000028.md) | [20.7](/filings/0001698530-25-000056.md) | [18.7](/filings/0001698530-25-000077.md) | [15.3](/filings/0001698530-25-000100.md) | [14.0](/filings/0001193125-26-352011.md) | [12.8](/filings/0001698530-26-000057.md) | [11.4](/filings/0001193125-26-352011.md) |
| Current liabilities | $m | [2.2](/filings/0001698530-24-000030.md) | [2.5](/filings/0001698530-25-000019.md) | [2.7](/filings/0001698530-24-000068.md) | [3.4](/filings/0001698530-24-000089.md) | [3.7](/filings/0001698530-24-000117.md) | [3.1](/filings/0001698530-26-000028.md) | [3.9](/filings/0001698530-25-000056.md) | [4.6](/filings/0001698530-25-000077.md) | [2.8](/filings/0001698530-25-000100.md) | [3.9](/filings/0001193125-26-352011.md) | [4.5](/filings/0001698530-26-000057.md) | [4.2](/filings/0001193125-26-352011.md) |
| Total liabilities | $m | [8.5](/filings/0001698530-24-000030.md) | [8.5](/filings/0001698530-25-000019.md) | [8.5](/filings/0001698530-24-000068.md) | [9.1](/filings/0001698530-24-000089.md) | [9.1](/filings/0001698530-24-000117.md) | [8.3](/filings/0001698530-26-000028.md) | [9.3](/filings/0001698530-25-000056.md) | [9.9](/filings/0001698530-25-000077.md) | [8.3](/filings/0001698530-25-000100.md) | [10.1](/filings/0001193125-26-352011.md) | [10.7](/filings/0001698530-26-000057.md) | [10.4](/filings/0001193125-26-352011.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.0](/filings/0001698530-24-000089.md) | not reported | [1.0](/filings/0001698530-24-000089.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [4.5](/filings/0001698530-24-000117.md) | [3.0](/filings/0001698530-26-000028.md) | [2.2](/filings/0001698530-25-000100.md) | [1.6](/filings/0001698530-25-000100.md) | [1.5](/filings/0001698530-25-000100.md) | [6.8](/filings/0001193125-26-352011.md) | [11.4](/filings/0001193125-26-352011.md) | [8.9](/filings/0001193125-26-352011.md) | [6.9](/filings/0001698530-25-000100.md) | [3.9](/filings/0001193125-26-352011.md) | [2.1](/filings/0001193125-26-352011.md) | [1.0](/filings/0001193125-26-352011.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,412) d](/filings/0001698530-24-000117.md) | [(816) d](/filings/0001698530-25-000019.md) | [(450)](/filings/0001698530-25-000056.md) | [(1,166) d](/filings/0001698530-25-000077.md) | [(449) d](/filings/0001698530-25-000100.md) | [(845) d](/filings/0001698530-26-000028.md) | [(1,598)](/filings/0001698530-26-000057.md) | [(2,282) d](/filings/0001193125-26-352011.md) | [(3,528) d](/filings/0001698530-25-000100.md) | [(1,147) d](/filings/0001698530-26-000028.md) | [(1,142)](/filings/0001698530-26-000057.md) | [(887) d](/filings/0001193125-26-352011.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001698530-24-000030.md) | [0.0 d](/filings/0001698530-24-000051.md) | not reported | not reported | [0.0 d](/filings/0001698530-25-000100.md) | [0.0 d](/filings/0001698530-26-000028.md) | not reported | not reported | [(106) d](/filings/0001698530-25-000100.md) | [(213) d](/filings/0001698530-26-000028.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,963](/filings/0001698530-24-000030.md) | [6,289](/filings/0001698530-24-000068.md) | [8,432](/filings/0001698530-24-000089.md) | [1,730](/filings/0001698530-24-000117.md) | [1,730](/filings/0001698530-25-000056.md) | [1,730](/filings/0001698530-25-000077.md) | [1,899](/filings/0001698530-25-000100.md) | [6,183](/filings/0001698530-26-000057.md) | [6,318](/filings/0001193125-26-352011.md) | [6,322](/filings/0001698530-25-000100.md) | [6,374](/filings/0001698530-26-000057.md) | [6,374](/filings/0001193125-26-352011.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,545,995 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-352011.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.